John Wiley & Sons : Are Steroids Used Too Much for Patients with Inflammatory Bowel Disease?
October 09, 2019 at 12:56 am EDT
Share
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn's disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months. In a large study published in Alimentary Pharmacology and Therapeutics, researchers at 19 centres in the UK report that, among 2,385 patients with inflammatory bowel disease, 14.8% showed evidence of steroid excess or dependency, and the steroid excess was judged avoidable in over 50% of cases.
The seven centres that had participated in a quality improvement programme had significantly fewer patients (11.5% versus 17.1%) receiving excess steroids.
'Looking at steroid prescribing for inflammatory bowel disease and trying to reduce steroid excess can be a powerful way to improve patient care and outcomes,' said lead author Christian P. Selinger, MD, MSc, MRCP, of St. James University Hospital.
Additional Information
Link to Study: https://onlinelibrary.wiley.com/doi/10.1111/apt.15497
About Journal
Alimentary Pharmacology & Therapeutics is an international journal of gastroenterology and hepatology.
The journal accepts systematic reviews, meta-analyses, randomised controlled trials and original papers concerned with Gastroenterology and Hepatology.
AP&T is particularly interested in therapies and diagnostics, including all aspects of translation from bench to bedside: identification of novel therapeutic targets, epidemiology, clinical trials, drug safety and meta-analyses.
About Wiley
Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at www.wiley.com.
Attachments
Original document
Permalink
Disclaimer
John Wiley & Sons Inc. published this content on 09 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 October 2019 04:55:10 UTC
John Wiley & Sons, Inc. is a knowledge company. The Company is engaged in providing research, publishing, and knowledge solutions. The Company's segments include Research, Learning, and Held for Sale or Sold. Research segment is a provide peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. The Learning segment provides scientific, professional, and education print and digital books, digital courseware to libraries, corporations, students, professionals, and researchers, as well as assessment services to businesses and professionals. The Company's Research Publishing products provide scientific, technical, medical, and scholarly journals, as well as related content and services, to academic, corporate, and government libraries, learned societies, and individual researchers, and other professionals.
JOHN WILEY & SONS, INC. 
